Venous thromboembolism is common in patients with cancer. However, no management
guidelines exist for venous thromboembolism specific to patients with advanced progressive …

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation
therapy is used to treat vte; however, patients with cancer have unique clinical …

Cancer-associated thrombosis is a frequent and costly complication in patients with cancer.
Significant morbidity and mortality not only result from thrombotic events, but may also occur …

BACKGROUND. The authors compared the relative efficacy and safety of low‐molecular‐
weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous …

Patients with cancer who develop venous thromboembolism (VTE) are at elevated risk for
recurrent thrombotic events, even during anticoagulant therapy. The clinical picture is further …

Cancer and its treatments are well-recognized risk factors for venous thromboembolism
(VTE). Although the incidence of VTE in cancer patients is not well documented, there is …

Patients with cancer are at increased risk of venous thromboembolism (VTE). In these
patients VTE is associated with substantial morbidity and complicates the clinical …

The occurrence of venous thromboembolism complicates the management of the patient
with malignant disease because of the need for anticoagulant therapy. Cancer patients have …

Venous thromboembolism (VTE) is a common complication in patients with cancer. The risk
of emergent VTE is four-to seven-fold higher in cancer patients compared to non-cancer …

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation
therapy has been shown to prevent vte; however, unique clinical circumstances in patients …